ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Jun 11, 2020 06:00 JST
Source:
Agilex Biolabs
Agilex Biolabs Encourages Biotechs to Move Delayed Trials to Australia at BIO Digital 2020
ADELAIDE, AUS, Jun 11, 2020 - (ACN Newswire) - Agilex Biolabs, Australia's largest specialist bioanalytical laboratory for clinical trials, encouraged biotechs to consider Australia for their clinical trials during a presentation at BIO Digital 2020.
Watch the BIO Digital 2020 presentation here:
https://www.bio.org/events/bio-digital/sessions/search?name=Agilex
The presentation by CEO Jason Valentine and moderated by VP Business Development Julia Jones details the current trials landscape in Australia and why biotechs wanting to avoid delays caused by COVID-19, can move their trials to Australia.
Australia's impressive COVID-19 management and the world's most attractive rebate on clinical trials costs are just a few of the reasons that make it an ideal location to restart delayed trials, according to Agilex Biolabs.
CEO Jason Valentine said:
"Australia has a group of proven top-tier trial providers that regularly work together so are fully engaged and in sync with processes and each other's requirements and capabilities. We have worked with all the trials service provider companies so can advise on which ones are the best fit for each study.
"The Agilex Biolabs team can offer an unbiased approach and advice depending on specific trial requirements. Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition."
Please Book a Briefing with us before you start your next clinical trial.
https://calendly.com/agilexbiolabs/15min
Australia: +61 8 8302 8777 | China: +86 21 8036 9483 | South Korea: +82 80 812 1255 | USA: +1 800 247 1909
Agilex Biolabs has launched a News Video Update about COVID-19 and clinical trials in Australia. Watch it here:
https://youtu.be/vZuHAYZ-GiE
About Agilex Biolabs
https://www.agilexbiolabs.com
Agilex Biolabs, Australia's leading bioanalytical laboratory, has more than 20 years' experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. We have successfully supported hundreds of preclinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and access to the world's most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.
Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser). Agilex offers pharmacodynamics services including immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, incuding Immunophenotyping, Receptor occupancy, and Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling PBMC assays and cellular mechanism of action assays (ie ADCC).
Agilex Biolabs, the only FDA-inspected lab of its type in the region, is located in Adelaide, South Australia in a science and biotech specialist hub. The biolabs has more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year they will analyse more than 60,000 samples for pharma/biotechs from US, Europe and APAC.
The company has just expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA.
See us featured in Endpoints
https://tinyurl.com/uqmkzcu
Media Contact:
Kate Newton
Media@AgilexBiolabs.com
Source: Agilex Biolabs
Sectors: BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
More Latest Release >>
Related Release
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory
May 12 2022 15:00 JST
Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies - OCT Webinar
October 19 2021 15:00 JST
Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research
September 24 2021 09:00 JST
Agilex Biolabs Partners with Endpoints News for the First Webinar on Rapid Vaccine Development in Australia
August 26 2021 13:00 JST
Premier of South Australia Launches $1.5m Vaccine and Immunobiology State-of-the art Laboratory for APAC Clinical Trials
July 14 2021 17:00 JST
Agilex Biolabs and Gyros Protein Technologies Partner for BioAnalysis Zone Webinar on Singlicate Analysis
May 31 2021 13:00 JST
Agilex Biolabs Partners with Endpoints News on Deconvoluting Inflammation and Immunology for Clinical Trials
May 21 2021 11:00 JST
Agilex Biolabs' Toxicology Tapped for SARS-CoV-2 Vaccine Research
May 17 2021 21:00 JST
Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results
April 30 2021 13:00 JST
Agilex Biolabs and B2S Life Sciences on Immunoassay Bioanalysis for Clinical Trials
April 29 2021 04:00 JST
More Press release >>